What is Eikon Therapeutics, Inc. 's stock-based comp?

Eikon Therapeutics, Inc. (EIKN) reported stock-based comp of $2.78M in Q1 2026.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

MYR GroupMYRG

$3.39M+45.1%

PBH

Prestige Consumer HealthcarePBH

$2.65M-3.1%

A10 NetworksATEN

$4.82M-19.9%

Macy'sM

$14M+7.7%

AgilysysAGYS

$6.02M+17.6%

UnifirstUNF

$3.67M+14.9%

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Market cap$514.86M—

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Eikon Therapeutics, Inc. 's stock-based comp?: Eikon Therapeutics, Inc. (EIKN) reported stock-based comp of $2.78M in Q1 2026.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.